The stock of Acorda Therapeutics Inc (NASDAQ:ACOR) is a huge mover today! About 163,553 shares traded hands. Acorda Therapeutics Inc (NASDAQ:ACOR) has declined 29.06% since April 26, 2016 and is downtrending. It has underperformed by 34.32% the S&P500.
The move comes after 8 months positive chart setup for the $971.26M company. It was reported on Nov, 29 by Barchart.com. We have $22.30 PT which if reached, will make NASDAQ:ACOR worth $29.14 million more.
Analysts await Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings on February, 9. They expect $-0.13 EPS, down 161.90% or $0.34 from last year’s $0.21 per share. After $-0.28 actual EPS reported by Acorda Therapeutics Inc for the previous quarter, Wall Street now forecasts -53.57% EPS growth.
Acorda Therapeutics Inc (NASDAQ:ACOR) Ratings Coverage
Out of 2 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Acorda Therapeutics has been the topic of 8 analyst reports since August 25, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating by Raymond James given on Tuesday, September 1. The firm has “Buy” rating given on Tuesday, September 1 by Aegis Capital. The rating was maintained by Aegis Capital with “Buy” on Wednesday, January 6. Cowen & Co maintained the stock with “Outperform” rating in Tuesday, August 25 report. The firm has “Neutral” rating given on Wednesday, March 30 by Goldman Sachs. TheStreet downgraded the shares of ACOR in a report on Tuesday, August 25 to “Buy” rating. The rating was maintained by JP Morgan on Tuesday, August 25 with “Neutral”. The stock has “Buy” rating given by Stifel Nicolaus on Tuesday, August 25.
According to Zacks Investment Research, “Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company’s lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.”
Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.24, from 1.13 in 2016Q1. The ratio dropped, as 32 funds sold all Acorda Therapeutics Inc shares owned while 45 reduced positions. 14 funds bought stakes while 73 increased positions. They now own 43.11 million shares or 7.66% less from 46.68 million shares in 2016Q1.
Northern Corporation has 502,976 shares for 0% of their US portfolio. Clinton Group holds 0.04% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 35,802 shares. Ls Advsrs Lc holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 1,911 shares. Moreover, Sphera Funds Mngmt Ltd has 0.65% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 98,000 shares. Blackrock Fund Advsr holds 0.02% or 3.42 million shares in its portfolio. Rhumbline Advisers accumulated 0% or 65,930 shares. Blackrock Limited Co has 63,384 shares for 0% of their US portfolio. Moreover, Evercore Wealth Mgmt Ltd Llc has 0% invested in Acorda Therapeutics Inc (NASDAQ:ACOR) for 400 shares. Mutual Of America Cap Management Ltd Liability Corp holds 0.04% or 66,458 shares in its portfolio. Thrivent Fincl For Lutherans holds 0% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 22,410 shares. Blackrock Institutional Trust Communications Na, a California-based fund reported 1.30M shares. Tfs Capital Ltd Liability Com holds 26,290 shares or 0.12% of its portfolio. Adage Prtn Ltd Liability Corporation owns 1.18M shares or 0.08% of their US portfolio. Tudor Invest Et Al holds 0.01% of its portfolio in Acorda Therapeutics Inc (NASDAQ:ACOR) for 13,546 shares. Voya Inv Ltd has 0% invested in the company for 20,702 shares.
Insider Transactions: Since June 8, 2016, the stock had 0 buys, and 5 sales for $168,893 net activity. $5,205 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) was sold by LAWRENCE DAVID. Batycky Richard P. sold $41,877 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Friday, October 21. Another trade for 500 shares valued at $13,660 was made by Wasman Jane on Friday, September 23. RAUSCHER STEVEN M also sold $30,224 worth of Acorda Therapeutics Inc (NASDAQ:ACOR) on Wednesday, June 8.
More news for Acorda Therapeutics Inc (NASDAQ:ACOR) were recently published by: Marketwatch.com, which released: “Acorda Therapeutics plummets as much as 13% on failed trial, discontinued drug …” on November 21, 2016. Fortune.com‘s article titled: “Acorda Therapeutics” and published on June 28, 2016 is yet another important article.
ACOR Company Profile
Acorda Therapeutics, Inc., incorporated on March 17, 1995, is a biopharmaceutical company. The Firm is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. The Company’s commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. The Company’s research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. The Company’s Ampyra (dalfampridine) Extended Release Tablets, 10 milligrams, is used as a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, which are short-acting drugs for the management of spasticity, and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company’s pipeline of neurological therapies addresses a range of disorders, including MS, Parkinson’s disease, chronic post-stroke walking deficits (PSWD), epilepsy and migraine.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.